Tango Therapeutics/TNGX

$11.69

-0.93%
-
1D1W1MYTD1YMAX

About Tango Therapeutics

Tango Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing precision medicines to help patients with cancer through addressing the specific genetic alterations that fuel the cancer. Its lead program, TNG908, is a methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. It is also developing TNG462, a more potent and selective PRMT5 inhibitor with improved pharmacokinetic properties as compared to TNG908. TNG260 is a small molecule inhibitor of the CoREST deacetylase complex that reverses checkpoint inhibitor resistance in serine-threonine kinase 11 (STK11) mutant preclinical models. Its TNG348 is an allosteric inhibitor of ubiquitin-specific protease 1 (USP1) for the treatment of BRCA-mutant and other homologous recombination-deficient (HRD+) cancers.

Ticker

TNGX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Barbara Weber

Employees

100

Headquarters

Boston, United States

TNGX Metrics

BasicAdvanced
$1.16B
Market cap
-
P/E ratio
-$1.11
EPS
0.91
Beta
-
Dividend rate

What the Analysts think about TNGX

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
49.1% upside
High $20.00
Low $16.00
$11.69
Current price
$17.43
Average price target

TNGX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-207.47% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$10.7M
-26.21%
Net income
$-22.2M
7.25%
Profit margin
-207.47%
45.34%

TNGX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 33.33%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.33
-$0.32
-$0.23
-$0.23
-
Expected
-$0.36
-$0.35
-$0.34
-$0.35
-$0.28
Surprise
-7.04%
-8.92%
-31.55%
-33.33%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Tango Therapeutics stock

Buy or sell Tango Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing